Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03278119 · ClinicalTrials.gov registry record
Sleep Aging and Risk for Alzheimer's 2.0
A clinical trial of Alzheimer Disease and Sleep Apnea, sponsored by NYU Langone Health.
- Active
- Registry status
- 158
- Enrollment target
- 1
- Study location
NCT03278119 is a study of Alzheimer Disease and Sleep Apnea that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 158 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03278119, a study of Alzheimer Disease and Sleep Apnea, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- 158 participants
- Enrollment target
- 1
- Study location
Study Summary
Age-related sleep changes and common sleep disorders like obstructive sleep apnea (OSA) may increase amyloid burden and represent risk factors for cognitive decline in the elderly. We will directly interrogate the brain using a 2-night nocturnal polysomnography (NPSG) and amyloid deposition using C-PiB PET/MR both at baseline and at the 24-month follow-up. This study has the potential to identify the mechanisms by which age-related sleep changes contribute to AD neurodegeneration in cognitively normal elderly, the group that could profit the most from sleep preventive strategies.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PET Scan and nocturnal polysomnography
Study Locations (1)
New York
- Healthy Brain Aging and Sleep Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2025-12-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03278119
The ClinicalTrials.gov registry entry for NCT03278119 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (94% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which PET Scan and nocturnal polysomnography is the first listed.
NCT03278119 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03278119 about?
NCT03278119 is a clinical study titled "Sleep Aging and Risk for Alzheimer's 2.0". Age-related sleep changes and common sleep disorders like obstructive sleep apnea (OSA) may increase amyloid burden and represent risk factors for cognitive decline in the elderly. We will directly interrogate the brain using a 2-night nocturnal polysomnography (NPSG) and amyloid deposition using C-...
What is the current status of trial NCT03278119?
This trial is currently active not recruiting. The enrollment target is 158 participants. The study started on 2018-05-01. Estimated completion is 2025-12-25.
What conditions does trial NCT03278119 study?
This clinical trial studies the following conditions: Alzheimer Disease, Sleep Apnea.
What interventions are being tested in trial NCT03278119?
The interventions under investigation include: PET Scan and nocturnal polysomnography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03278119?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03278119 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.